|
News/ Information:
|
New clinical data on lead oncology compounds presented at ASCO 2009: Oncology experts about results of the LUX-Lung study programme in lung cancer. |
|---|---|
|
Website:
|
Progress in Oncology
Background information for medical media outside the US only
Infomation about cancer
Compound information
Further oncology information
Releated Information
-
Prof. James Spicer
Senior Lecturer, Cancer Studies Division, King's College London, and Consultant in Medical Oncology, Guy's and St. Thomas' Foundation Hospital NHS Trust, London, UK
Dr. James Spicer is Senior Lecturer in the Cancer Studies Division of King's College London, and Honorary Consultant in Medical Oncology at Guy's and St Thomas' Foundation Hospital NHS Trust.
-
Dr Rolf Kaiser
International Medical Project Leader for Phase I-III studies in Oncology, Boehringer Ingelheim, Biberach, Germany
Dr. Kaiser has received several awards for teaching and research during his career, including the Antiemetic Research Award from the Multinational Association of Supportive Care in Cancer (MASCC) in 2003 for his work in exploring the role of pharmacogenetics in emesis. His research has been extensively published in a range of leading international peer-reviewed journals, including the Journal of Clinical Oncology and The Lancet Oncology.
-
Videos
-
-
Images from Progress in Oncology
-
A tumor needs oxigen and nutrition to grow
-
Angiogenesis: Vessels invading the tumor transport oxigen and nutrition
-
Angiogenesis Inhibition: Vessels degenerate or withdraw from tumor
-
Signal transduction: a ligand binds to a growth factor receptor and initiates growth signalling cascade
-
The EGFR/Her2 Receptor Family
-
Signal Transduction: BIBW 2992 irreversibly block the growth factor receptor
-
Laboratory work in Research and Development
-
R&D Laboratory Work
-
